Next Article in Journal
Effects of Storage Time and Temperature on Antioxidants in Juice from Momordica charantia L. and Momordica charantia L. var. abbreviata Ser.
Next Article in Special Issue
A Walk through Recent Nitro Chemistry Advances
Previous Article in Journal
A DFT Study on FeI/FeII/FeIII Mechanism of the Cross-Coupling between Haloalkane and Aryl Grignard Reagent Catalyzed by Iron-SciOPP Complexes
Previous Article in Special Issue
Synthesis and Properties of NitroHPHAC: The First Example of Substitution Reaction on HPHAC
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 16
10.3390/molecules25163613
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study

by
Evgeny V. Pospelov
1,2,
Ivan S. Golovanov
1,
Sema L. Ioffe
1 and
Alexey Yu. Sukhorukov
1,3,*
1
N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia
2
Department of Chemistry, M.V. Lomonosov Moscow State University, 119991 Moscow, Russia
3
Department of Innovational Materials and Technologies Chemistry, Plekhanov Russian University of Economics, 117997 Moscow, Russia
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(16), 3613; https://doi.org/10.3390/molecules25163613
Submission received: 3 July 2020 / Revised: 3 August 2020 / Accepted: 4 August 2020 / Published: 8 August 2020
(This article belongs to the Special Issue Nitro Compounds and Their Derivatives in Organic Synthesis)
Browse Figures
Review Reports Versions Notes

Abstract

:
An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangement of the corresponding 1,2-oxazine-N-oxide. The latter was assembled by a (4 + 2)-cycloaddition between the suitably substituted nitroalkene and vinyl ether. Facile acetal epimerization at the C-6 position in 1,2-oxazine ring was observed in the course of reduction with NaBH3CN in AcOH. Density functional theory (DFT) calculations suggest that the epimerization may proceed through an unusual tricyclic oxazolo(1,2)oxazinium cation formed via double anchimeric assistance from a distant acyloxy group and the nitrogen atom of the 1,2-oxazine ring.

Graphical Abstract

1. Introduction

Cyclic nitronates (1,2-oxazine-N-oxides 1 and isoxazoline-N-oxides 2) are useful intermediates in the synthesis of complex nitrogen containing scaffolds due to their versatile reactivity as 1,3-dipoles and accessibility from nitroalkenes (Scheme 1a) [1,2,3,4,5,6,7,8,9,10]. Denmark’s group extensively exploited the inter- and intramolecular (3 + 2)-cycloaddition reactions with six-membered cyclic nitronates 1 to construct various bi- and polycyclic nitroso acetal frameworks 3, which were then converted into fused pyrrolidine derivatives by an intramolecular reductive amination (Scheme 1b) [1,11]. Using this strategy, total syntheses of numerous pyrrolizidine and indolizidine alkaloids [12,13,14], as well as (5.5.5.5)- and (5.5.5.4)-azafenestanes [15,16], were accomplished.
Our group has a long-term interest in developing another approach towards the modification of cyclic nitronates, which utilizes C–H functionalization of the position next to the nitronate group (α-C-atom, Scheme 1c) [17]. Some time ago, we demonstrated that upon silylation, cyclic nitronates 1 and 2 are transformed into N-siloxyenamines 4, in which the double bond is shifted to the exocyclic α-position [18]. Enamines 4 exhibit umpolung reactivity and react with nucleophiles in the presence of Lewis acids (LA) to give α-substituted cyclic oxime ethers 5 (1,2-oxazines or isoxazolines) via SN’ substitution of TMSO-group (Scheme 1c). Using this approach, nucleophilic halogenation [19], oxygenation [20,21,22], azidination [23] of cyclic nitronates were performed (route 1). Although we succeeded in using this methodology in the total synthesis of some pharmaceutical molecules, in the case of nitronates having acid-sensitive groups (e.g., acetals), it proved to be not very efficient (vide infra) [20,24,25].
Recently, we designed another strategy for the site-selective functionalization of cyclic nitronates 1 and 2 via acylation with acyl halides/Et3N (Scheme 1d) [26]. The initially formed N-acyloxyenamines 6 undergo a spontaneous (3,3)-rearrangement to give α-acyloxy-substituted cyclic oxime ethers 7 (route 2). This tandem C–H oxygenation process could be performed under very mild conditions. At present, we are testing the scope and limitation of this method in the total synthesis of some model target molecules to compare its efficacy with our previous C–H functionalization methods. In this study, a potent GlaxoSmithKline’s phosphodiesterase 4 (PDE4) inhibitor CMPO [27,28,29], which was previously synthesized using route 1 [24,30], was chosen as a target molecule.
Scheme 2 depicts our previous synthetic route to CMPO. The fused pyrrolidine core was prepared by carbamylation of a trans-3-aryl-substituted prolinol 15. The latter was accessed in our strategy by the reductive contraction of the 1,2-oxazine ring in the intermediate 14, which was prepared by the stereoselective hydride reduction of the 5,6-dihydro-4H-1,2-oxazine 13 [24]. This intermediate was synthesized by the reduction of the ONO2-group in the corresponding nitroxy-substituted 1,2-oxazine 12. Introduction of the nitroxy-group was accomplished by the LA-assisted functionalization of the methyl group in the N-oxide 10 using route 1 described above (see Scheme 1c). The required N-oxide 10 was assembled in a stereoselective manner by the (4 + 2)-cycloaddition of nitroalkene 8 with the vinyl ether 9 bearing Whitesell’s chiral auxiliary group ((+)-trans-2-phenyl-1-cyclohexanol ether).
Oxygenation of the methyl group in the N-oxide 10 proved to be challenging, and several methods were tested (Scheme 3). N-Siloxy,N-oxyenamine 16 was generated from the N-oxide 10 under mild conditions and then subjected to the LA-assisted nucleophilic addition of the bromide anion [24,25]. However, the desired 3-bromomethyl-1,2-oxazine 11, which served as a precursor to nitrate 12, was formed in moderate yields (best results are shown in Scheme 3a). Another issue was the epimerization of the sensitive C-6 acetal stereocenter leading to a mixture of 4,6-trans/4,6-cis-diastereomers 11 and 11′, which had to be separated by column chromatography (Scheme 3a,b). Unfortunately, the epimer 11′ could not be used in the synthesis of CMPO as it produced the undesired 3,4-cis-stereoisomer upon the reduction of the C=N bond in 5,6-dihydro-4H-1,2-oxazine ring on the later stages of the synthesis (Scheme 3c) [25].
The reason for the epimerization may lie in the mechanism of the LA-promoted reaction of N-oxyenamines with nucleophiles, which involves heterolytic cleavage of the N–O bond (Scheme 3b). Experimental [20,22] and computational data [22] suggest that the SN’ substitution of the TMSO-group may proceed through an epimerizable N-vinyl,N-oxynitrenium cation C1. In our later study, we were able to optimize the epimerization ratio to 6: 1 by using Cr(NO3)3 as both a mild Lewis acid and the source of the nitrate anion [20]. However, the yield of nitroxy-derivative 12 was still not very high (ca. 40% from nitronate 10, Scheme 3a). Thus, further optimization of the C–H functionalization stage was reasonable.

2. Results

We speculated that the pericyclic (3,3)-rearrangement of N-acyloxyenamine intermediate I1 generated by the acylation of nitronate 10 may proceed without any epimerization of the C-6 stereogenic center. To test this idea, cyclic nitronate 10 was treated with pivaloyl chloride/Et3N (1.5/2.0 equiv.) under conditions previously optimized for model 1,2-oxazine-N-oxides (MeCN, −30 °C, 2 h) [26]. The desired pivalate 17 was formed in a 61% yield together with some amount of unreacted N-oxide 10. After a short optimization of conditions, we found that the use of a bigger access of the PivCl/Et3N system (2.0/2.5 equiv.) and prolonged reaction time (18 h) at lower temperature resulted in an increase in the yield up to 76% (Scheme 4). Gratifyingly, no noticeable epimerization at the C-6 position was observed under these conditions.
We further investigated whether pivalate 17 could be used in the synthesis of CMPO. Hydrogenolysis of the pivalate group in 17 (to give alcohol 13) prior the reduction is challenging since 5,6-dihydro-4H-1,2-oxazines are known to undergo fragmentation via a retro-[4+2]-cycloaddition process under the action of bases [31]. Therefore, pivalate 17 was subjected to the hydride reduction with NaBH3CN in acetic acid (Scheme 5). Surprisingly, the reaction produced two separable isomeric products 18 and 18′ in 3: 1 ratio (62% combined yield, 91% based on converted 17). From the coupling constants in 1H-NMR spectra, it was deduced that both isomers had trans-arrangement of the substituents at the C-3 and C-4 atoms, while the configuration of the C-6 stereocenter was different. Thus, the C-6 acetal moiety underwent epimerization in the course of the reduction (see Discussion section). The amount of 4,6-cis-isomer 18′ increased with time, demonstrating that the isomerization took place in the reduced product 18 and not in the starting compound 17. This is also confirmed by the fact that stereisomers 18 and 18′ had same configuration of the newly formed C-3 stereocenter. If the epimerization preceded the reduction, the C-6 epimerized 5,6-dihydro-4H-1,2-oxazine 17′ would also give the reduced product with the 3,4-cis-disposition of substituents (see Scheme 3c).
Isomers 18 and 18′ could be almost equally used in the reductive contraction of the 1,2-oxazine ring [32], since both produced the same amino aldehyde intermediate I3 upon cleavage of the N–O bond followed by fragmentation of the hemiacetal I2 (Scheme 6). Subsequent intramolecular reductive amination in the intermediate I3 and protection with the Boc-group afforded the desired prolinol ester 19. Hence, the separation of epimers 18 and 18′ was not required and a mixture could be converted into the product 19 in a 61% yield. The chiral auxiliary alcohol (trans-2-phenylcyclohexanol) was recovered at this stage in 77% yield.
On the next step, careful saponification of the pivalate moiety in pyrrolidine 19 with KOH in aqueous methanol gave Boc-prolinol 20 in 84% yield (Scheme 6). It is noteworthy that hydrolysis of the Boc-group was also observed to some extent under these conditions. For this reason, the reaction mixture was treated with Boc2O after neutralization to convert the unprotected prolinol into the N-Boc-derivative 20, which was isolated by column chromatography.
Finally, deprotection of the N-Boc moiety with TFA and treatment of the resulting prolinol trifluoroacetate with Im2CO/Et3N afforded the desired PDE4 inhibitor CMPO (Scheme 6). Thus, the asymmetric synthesis of PDE4 inhibitor CMPO was completed in seven steps from a known nitroalkene 8 in 8% overall yield. Chiral HPLC analysis revealed the enantiomeric purity of the product > 97% ee. The racemic sample of CMPO for HPLC analysis was prepared according to the same synthetic sequence starting from the racemic trans-2-phenylcyclohexanol.

3. Discussion

Epimerization of the acetal moiety in the course of the hydride reduction of 5,6-dihydro-4-H-1,2-oxazine 17 is of special note. In the previously reported hydride reduction of 1,2-oxazine 13 possessing a free hydroxymethyl group, no epimerization at the C-6 atom was observed (cf. data in Scheme 2; Scheme 5) [24]. We hypothesized that such a difference in the behavior of 3-hydroxymethyl- and 3-acyloxymethyl-substituted 1,2-oxazines 13 and 17 may be attributed to an anchimeric assistance from the carbonyl group, which stabilizes the intermediate cation C2 [33] by forming a bridged system with an eight-membered ring (cation C3). In carbohydrates, a similar anchimeric assistance of the acyloxy group from the distant 1,4-position has been proposed, yet it was not confirmed unambiguously by experimental data [34,35,36,37]. In our case, density functional theory (DFT) calculations at the MN15/Def2TZVP level of theory (see Supplementary material for details) revealed that the bridged cation C3 is much less stable compared to the initial monocyclic cation C2. Interestingly, the formation of a third ring between the nitrogen atom and the acyloxy group may lead to a tricyclic cation C4, which is predicted to be much more stable than the mono- or bicyclic structures C2 and C3 (Scheme 7). The formation of such a stable tricyclic cation as an intermediate or a resting state may account for the observed facile epimerization of pivalate 18. The higher thermodynamic stability of the 4,6-cis-isomer 18′ over the 4,6-trans-isomer 18, as shown by DFT calculations, is likely to be the driving force for the epimerization at the C-6 atom.
Another remarkable observation was that 1,2-oxazine 18 (as well as its precursor 17) did not undergo epimerization in acetic acid (rt, 2 h). Isomerization to the cis-isomer 18′ was observed only in the presence of NaBH3CN. Hence, the fragmentation of the acetal moiety is most likely promoted by some Lewis acidic boron species generated from NaBH3CN in acidic medium. Indeed, slow epimerization of 1,2-oxazine 18 was observed upon treatment of 18 with B(OBu)3 or BF3·Et2O in acetic acid.
It is noteworthy that an anchimeric-assisted epimerization in 1,2-oxazine series has not been reported previously. Moreover, to our knowledge, this is the first reported example of a remote neighboring group participation from the 1,4-position in a six-membered ring confirmed by DFT calculations [38,39,40]. The formation of an eight-membered ring in this case may be driven by an unusual secondary anchimeric interaction involving the nitrogen atom of the 1,2-oxazine ring leading to an unusual tricyclic oxazolo(1,2)oxazinium cation C4.

4. Materials and Methods

All reactions were carried out in oven-dried (150 °C) glassware. NMR spectra (Bruker AM 300 spectrometer, Karlsruhe, Germany) were recorded at room temperature (if not stated otherwise) with residual solvents peaks as an internal standard. Peak multiplicities are indicated by s (singlet), d (doublet), t (triplet), dd (doublet of doublets), q (quartet), quint (quintet), ddd (doublet of doublets of doublets), tt (triplet of triplets), tdd (triplets of doublets of doublets), m (multiplet), br (broad). The numeration of atoms used in the assignment of NMR spectra is given in Figure 1.
HRMS were measured on the electrospray ionization (ESI) (Bruker MicroTOF, Karlsruhe, Germany) instrument with a time-of-flight (TOF) detector. Concentrations c in optical rotation angles are given in g/100 mL. [α]D values are given in 10−1 deg cm2 g−1. Column chromatography was performed using Kieselgel (Merck, Germany) 40–60 μm 60A. Analytical thin-layer chromatography was performed on silica gel plates with QF 254. Visualization was accomplished with UV light and solution of anisaldehyde/H2SO4 in ethanol. Chiral HPLC analysis was performed on a chromatograph with a UV-VIS photodiode array detector (Shimadzu LC-20, Shimadzu, Japan). All reagents were commercial grade and used as received. Et3N, dichloromethane (DCM), and MeCN were distilled over CaH2 prior to the experiments; MeOH, hexane and ethyl acetate were distilled without drying agents.
(+)-(4S,6S)-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-methyl-6-(((1S,2R)-2-phenylcyclohexyl)oxy)-5,6-dihydro-4H-1,2-oxazine 2-oxide (+)-10 and the corresponding racemate rac-10 were synthesized according to the previously reported procedure from nitroalkene 8 and vinyl ether 9 [25]. In most experiments, very similar yields in enantiomeric and racemic series were obtained. In Schemes and Procedures, the best yields among two series are given if not otherwise stated.
Oxygenation of nitronate 10. Enantipure or racemic nitronate 10 (347 mg, 0.72 mmol) was dissolved in dry acetonitrile (1.7 mL) in a Schlenk tube under argon atmosphere, and then Et3N (251 μL, 1.8 mmol) was added. The solution was cooled to −40 °C and pivaloyl chloride (174 μL, 1.41 mmol) was added. The reaction mixture was stirred at ca. −40 °C for 2 h and then kept in a freezer (ca. −25 °C) overnight. The mixture was diluted with EtOAc (5 mL) and transferred into a separating funnel containing EtOAc (20 mL) and 0.25 M aq. NaHSO4 solution (20 mL). The aqueous layer was extracted with EtOAc (20 mL), the combined organic layers were washed with water (30 mL) and brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was subjected to a column chromatography on silica gel (Hexane/EtOAc = 10/1) to give 311 mg (76%) of enantiopure or racemic pivalate 17.
(1S,2R,4S,6S)- and (1S*,2R*,4S*,6S*)-(4-(3-(cyclopentyloxy)-4-methoxyphenyl)-6-((2-phenylcyclohexyl)oxy)-5,6-dihydro-4H-1,2-oxazin-3-yl)methyl pivalate (17). Rf = 0.44 (hexane/EtOAc = 3/1). 1H-NMR (300 MHz, COSY, HSQC, CDCl3) δ 7.41–7.13 (m, 5H, H14, H15, H16), 6.75 (d, J = 8.2 Hz, 1H, H23), 6.57 (dd, J = 8.2, 2.1 Hz, 1H, H22), 6.53 (d, J = 2.2 Hz, 1H, H26), 5.36 (dd, J = 2.7, 2.5 Hz, 1H, Heq6), 4.71 (m, 1H, H28), 4.08 (d, J = 13.5 Hz, 1H, H17′), 4.02 (ddd, J = 10.3, 10.2, 4.0 Hz, 1H, Hax7), 3.98 (d, J = 13.5 Hz, 1H, H17′’), 3.80 (s, 3H, H27), 2.92 (dd, J = 11.9, 7.7 Hz, 1H, Hax4), 2.61 (ddd, J = 11.1, 10.3, 3.6 Hz, 1H, Hax8), 2.37 (m, 1H, H12), 2.01 (ddd, J = 13.0, 7.7, 2.7 Hz, 1H, Heq5), 1.98–1.73 (m, 10H, Hax5, H9′, H10, H29, H30′), 1.70–1.52 (m, 3H, H9”, H30′’), 1.50–1.28 (m, 3H, H11, Heq12), 1.10 (s, 9H, H20). 13C-NMR (75 MHz, HSQC, CDCl3) δ 177.4 (C18), 155.3 (C3), 149.3 and 147.9 (C24 and C25), 144.4 (C13), 131.1 (C21), 128.0 and 127.8 (2 C14 and 2 C15), 125.9 (C16), 120.7 (C22), 114.9 (C26), 112.2 (C23), 91.0 (C6), 80.4 (C28), 76.1 (C7), 63.6 (C17), 56.1 (C27), 50.7 (C8), 38.6 (C19), 34.3 (C9), 33.8 (C4), 32.8 and 32.7 (C29 and C29′), 32.5 (C5), 30.6 (C12), 27.1 (3 C20), 26.1 (C11), 24.7 (C10), 24.0 (C30 and C30′). HRMS (ESI): m/z calcd. for [C34H46NO6]+ 564.3320, found 564.3316 [M + H]+.
(+)-(1S,2R,4S,6S)-17. Colorless oil. [α]D = +188.6 (c = 0.09, EtOAc, 20 °C). rac-17. Colorless oil.
Hydride reduction of 5,6-dihydro-4H-1,2-oxazine 17. Procedure 1: Enantiopure or racemic pivalate 17 (80 mg, 0.14 mmol) was dissolved in acetic acid (0.8 mL) and sodium cyanoborohydride (120 mg, 1.9 mmol) was added to the solution upon intensive stirring. The reaction mixture was stirred under argon for 30 min at rt, then diluted with EtOAc (3 mL) and transferred into a separating funnel containing EtOAc (20 mL) and a sat. aq. NaHCO3 solution (20 mL). The aqueous layer was extracted with EtOAc (20 mL). The combined organic layers were washed with sat. aq. NaHCO3 solution (20 mL) and brine (40 mL), then dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected to a column chromatography on silica gel (Hexane/EtOAc = 10/1→5/1→3/1) to yield 49 mg (62%) of a mixture of 1,2-oxazines 18 and 18′ (d.r. 3: 1). Also, 26 mg (33%) of unreacted pivalate 17 was isolated from the column chromatography.
Procedure 2: Enantiopure or racemic pivalate 17 (190 mg, 0.34 mmol) was dissolved in acetic acid (1.8 mL) and sodium cyanoborohydride (250 mg, 3.97 mmol) was added to the solution upon intensive stirring. The reaction mixture was stirred under argon at rt for 1.7 h, then diluted with EtOAc (3 mL) and transferred into a separating funnel containing EtOAc (20 mL) and a sat. aq. NaHCO3 solution (20 mL). The aqueous layer was extracted with EtOAc (20 mL). The combined organic layers were washed with sat. aq. NaHCO3 solution (20 mL) and brine (40 mL), then dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected to a column chromatography on silica gel (Hexane/EtOAc = 10/1→5/1→3/1) to yield 48 mg (25%) of the fast moving isomer 18 and 69 mg (36%) of the slow moving isomer 18′.
((3R,4S,6S)- and (3R*,4S*,6S*)-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-6-(((1S,2R)-2-phenylcyclohexyl)oxy)-1,2-oxazinan-3-yl)methyl pivalate (18). Colorless oil (both enantiopure and racemic). Rf = 0.37 (hexane/EtOAc = 3/1). 1H-NMR (300 MHz, COSY, HSQC, CDCl3) δ 7.55–7.32 (m, 4H, H14, H15), 7.29–7.21 (m, 1H, H16), 6.76 (d, J = 8.0 Hz, 1H, H23), 6.61 (dd, J = 8.0, 2.1 Hz, 1H, H22), 6.59 (br s, 1H, H26), 4.99 (d, J = 3.0 Hz, 1H, H6), 4.79–4.68 (m, 1H, H28), 4.03 (br d, J = 10.7 Hz, 1H, Hax2), 3.80 (s, 3H, H27), 3.78 (ddd, J = 10.0, 10.0, 3.9 Hz, 1H, Hax7), 3.51 (dd, J = 11.8, 2.8 Hz, 1H, H17′), 3.22 (br ddd, J = 10.7, 9.8, 8.5 Hz, 1H, Hax3), 3.08 (dd, J = 11.8, 8.5 Hz, 1H, H17′’), 2.68 (ddd, J = 12.3, 10.3, 3.7 Hz, 1H, Hax8), 2.32 (ddd, J = 11.9, 11.9, 4.5 Hz, 1H, Hax4), 2.21 (br d, J = 10.6 Hz, 1H, Hax12), 2.05–1.75 (m, 11H, H5, H9′, H10, H29, H30′), 1.70–1.54 (m, 3H, H9”, H30′’), 1.48–1.25 (m, 3H, H11, Heq12), 1.12 (s, 9H, H20). 13C-NMR (75 MHz, HSQC, HMBC, DEPT135, CDCl3) δ 178.1 (C18), 149.1 and 147.8 (C24 and C25), 144.5 (C13), 133.9 (C21), 128.8 and 128.0 (2 C14 and 2 C15), 126.9 (C16), 119.5 (C22), 114.2 (C26), 112.3 (C23), 93.5 (C6), 80.5 (C28), 77.7 (C7), 63.3 (C17), 60.1 (C3), 56.1 (C27), 50.7 (C8), 38.6 (C19), 37.2 (C4), 37.0 (C5), 33.3 (C9), 32.7 and 32.8 (C29 and C29′), 31.3 (C12), 27.1 (3 C20), 26.0 (C11), 24.8 (C10), 24.0 (C30 and C30′). HRMS (ESI): m/z calcd. for [C34H48NO6]+ 566.3476, found 566.3474 [M + H]+.
((3R,4S,6R)- and (3R*,4S*,6R*)-4-(3-(Cyclopentyloxy)-4-methoxyphenyl)-6-(((1S,2R)-2-phenylcyclohexyl)oxy)-1,2-oxazinan-3-yl)methyl pivalate (18′). Characterized in mixture with 18 (d.r. 18/18′ = 1: 4). Colorless oil (both enantiopure and racemic). Rf = 0.30 (hexane/EtOAc = 3/1). 1H-NMR (300 MHz, COSY, HSQC, CDCl3) δ 7.55–7.32 (m, 5H, H14, H15, H16), 6.79 (d, J = 8.2 Hz, 1H, H23), 6.60 (dd, J = 8.2, 2.2 Hz, 1H, H22), 6.55 (d, J = 2.2 Hz, 1H, H26), 5.43 (d, J = 10.4 Hz, 1H, H2), 5.28 (d, J = 2.9 Hz, 1H, H6), 4.73 (m, 1H, H28), 3.93 (ddd, J = 10.3, 10.2, 4.0 Hz, 1H, H7), 3.81 (s, 3H, H27), 3.59 (d, J = 12.9 Hz, 1H, H17), 3.48 (ddd, J = 11.2, 10.4, 5.7 Hz, 1H, Hax3), 3.38 (dd, J = 12.9, 5.7 Hz, 1H, H17), 2.71 (ddd, J = 10.6, 10.3, 3.3 Hz, 1H, Hax8), 2.63 (ddd, J = 12.5, 11.2, 4.0 Hz, 1H, Hax4), 2.24 (br d, J = 11.9 Hz, 1H, Hax12), 2.06 (td, J = 13.3, 12.5, 2.9 Hz, 1H, Hax5), 1.99–1.76 (m, 10H, Heq5, H9′, H10, H29, H30′), 1.72–1.53 (m, 3H, H9”, H30′’), 1.53–1.25 (m, 3H, H11, Heq12), 1.10 (s, 9H, H20). 13C-NMR (75 MHz, HSQC, HMBC, DEPT135, CDCl3) δ 177.4 (C18), 149.9 and 148.2 (C24 and C25), 143.7 (C13), 130.6 (C21), 129.6 (C16), 127.7 and 127.5 (2 C14 and 2 C15), 120.0 (C22), 113.7 (C26), 112.4 (C23), 95.2 (C6), 80.7 (C28), 78.5 (C7), 65.8 (C3), 61.3 (C17), 56.0 (C27), 50.5 (C8), 38.5 (C19), 36.7 (C4), 36.4 (C5), 33.1 (C9), 32.8 and 32.7 (C29 and C29′), 30.7 (C12), 27.0 (3 C20), 25.8 (C11), 24.4 (C10), 24.0 (C30 and C30′). HRMS (ESI): m/z calcd. for [C34H48NO6]+ 566.3476, found 566.3476 [M + H]+.
Hydrogenation of 1,2-oxazines 18 and 18′. A glass vial was charged with a solution of enantiopure 1,2-oxazine 18 (48 mg, 0.086 mmol) and Boc2O (58 mg, 0.264 mmol) in methanol (0.5 mL). A suspension of Raney nickel (ca. 100 mg, prepared from 50% slurry in water) in methanol (ca. 0.5 mL) was added, and the vial was placed in a steel autoclave, which was then flushed and filled with hydrogen to a pressure of ca. 40 bar and heated to 50 °C. The hydrogenation was conducted for 2 h with intensive stirring. Then, the autoclave was cooled to rt, slowly depressurized, and the catalyst was removed using a magnet and washed with methanol. The solution was concentrated to dryness under reduced pressure. The residue was subjected to a column chromatography on silica gel (hexane/EtOAc = 20/1→10/1) to yield 31 mg (74%) of N-Boc pyrrolidine 19. The column was then washed with hexane/EtOAc = 5/1 to recover (+)-trans-2-phenylcyclohexanol (12 mg, 77%).
Application of the same procedure for the reduction of enantiopure 1,2-oxazine 18′ (69 mg, 0.13 mmol) afforded 36 mg (60%) of N-Boc pyrrolidine 19 and 15 mg (66%) of (+)-trans-2-phenylcyclohexanol.
Application of the same procedure for the reduction of a mixture of racemic 1,2-oxazines rac-18 and rac-18′ (90 mg, 0.159 mmol, d.r. 1: 1.4) afforded 46 mg (61%) of racemic N-Boc pyrrolidine rac-19.
Tert-butyl (2R,3S)- and (2R*,3S*)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-((pivaloyloxy)methyl)pyrrolidine-1-carboxylate (19). Rf = 0.30 (hexane/EtOAc = 3/1). 1H-NMR (300 MHz, 320K, COSY, HSQC, CDCl3) δ 6.82 (d, J = 8.7 Hz, 1H, H15), 6.75–6.70 (m, 2H, H14 and H21), 4.76 (m, 1H, H18), 4.41–4.26 (m, 1H, H9′), 4.20 (br d, J = 9.9 Hz, 1H, H9′’), 4.11–3.88 (br m, 1H, H2), 3.84 (s, 3H, H17), 3.77–3.62 (br m, 1H, H5′), 3.46–3.31 (m, 1H, H5′’), 3.29–3.10 (br m, 1H, H3), 2.35–2.18 (m, 1H, H4′), 2.01–1.76 (m, 7H, H4′’, H19, H20′), 1.72–1.54 (m, 2H, H20′’), 1.49 (s, 9H, H8), 1.21 (s, 9H, H12). 13C-NMR (75 MHz, HSQC, DEPT135, CDCl3) δ 178.2 (C10), 154.2 (C6), 148.9 and 147.9 (C16 and C22), 135.1 (C13), 119.2 (C14), 114.0 (C21), 112.3 (C15), 80.5 (C18), 80.0 (C7), 63.5 (br, C9), 63.1 (br, C2), 56.2 (C17), 47.2 (C3), 46.3 (C5), 38.8 (C11), 32.8 (C19 and C19′), 31.8 (C4), 28.5 (3 C8), 27.2 (3 C12), 24.0 (C20 and C20′) (signals are broadened due to the presence of N-Boc rotamers). HRMS (ESI): m/z calcd. for [C27H42NO6]+ 476.3007, found 476.3006 [M + H]+.
(−)-(2R,3S)-19. Colorless oil, [α]D = −19.0 (c = 1, EtOAc, 24 °C). rac-19. Colorless oil.
Saponification of pivalate 19. Enantiopure or racemic pivalate 19 (67 mg, 0.14 mmol) was dissolved in MeOH (2.8 mL) and a solution of KOH (237 mg, 4.2 mmol) in H2O (1.4 mL) was added. The mixture was stirred at room temperature for 24 h. Then, acetic acid (0.4 mL) was added and the reaction mixture was stirred for 5 min. The resulting solution was concentrated in vacuum. To the residue, MeOH (2 mL) and Boc2O (0.065 g, 0.28 mmol) were added and the resulting solution was stirred for 1 h. Then, volatiles were removed in vacuum and the residue was subjected to a column chromatography on silica gel (hexane/EtOAc = 5/1→3/1→1/1) to yield 46 mg (84%) of prolinol 20.
Tert-butyl (2R,3S)- and (2R*,3S*)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (20). Rf = 0.21 (hexane/EtOAc = 1/1). 1H-NMR (300 MHz, COSY, HSQC, CDCl3) δ 6.81 (d, J = 7.6 Hz, 1H, H13), 6.76 (d, J = 7.6 Hz, 1H, H12), 6.74 (s, 1H, H16), 5.13–4.88 (br, 1H, H10), 4.77 (m, 1H, H18), 3.97–3.85 (br m, 1H, H2), 3.83 (s, 3H, H17), 3.80–3.66 (br m, 2H, H9′, H5′), 3.63 (dd, J = 11.5, 6.8 Hz, 1H, H9′’), 3.44–3.27 (br m, 1H, H5′’), 2.89–2.79 (br m, 1H, H3), 2.22–2.07 (br m, 1H, H4′), 2.02–1.75 (m, 7H, H20′, H19, H4′’), 1.67–1.57 (m, 2H, H20′’), 1.51 (s, 9H, H8). 13C-NMR (75 MHz, HSQC, DEPT135, CDCl3) δ 156.8 (C6), 149.2 and 147.9 (C14 and C15), 133.3 (C11), 119.7 (C12), 114.5 (C16), 112.3 (C13), 80.5 (C18), 80.4 (C7), 67.1 (C2), 66.1 (C9), 56.2 (C17), 47.4 (C3), 47.0 (C5), 32.9 and 32.8 (C-4, C19 and C19′), 28.5 (3 C8), 24.0 (C20 and C20′). HRMS (ESI): m/z calcd. for [C22H33NO5Na]+ 414.2251, found 414.2247 [M + Na]+.
(−)-(2R,3S)-20. Colorless oil, [α]D = −9.3 (c = 1, EtOAc, 24 °C). rac-20. Colorless oil.
Synthesis of (−)- and rac-CMPO. To a stirred solution of enantiopure or racemic prolinol 20 (45 mg, 0.115 mmol) in DCM (0.9 mL) was added CF3COOH (0.18 mL, 2.4 mmol) at 0–5 °C. The cooling bath was removed, and the solution was stirred for 1 h. Then, volatiles were removed under reduced pressure and the residue was dried until constant weight. The resulting trifluoroacetate was dissolved in DCM (0.85 mL), and Et3N (0.08 mL, 0.58 mmol) and 1,1′-carbonyldiimidazole (47 mg, 0.29 mmol) were added at rt. The solution was stirred for 18 h at rt, and then concentrated under reduced pressure. The product was isolated by column chromatography on silica gel (hexane/EtOAc = 3/1) followed by recrystallization from hexane\diethyl ether (ca. 1: 1). Yield: 18 mg (49%). 1H NMR spectra were in agreement with previously published data [24].
(−)-(7S,7aR)-CMPO. White solid. Mp = 134–137 °C (lit.[24] 137–139 °C). HPLC analysis: ee > 97% (RT 9.8 min; column CHIRALPAK IA-3 (15 cm); solvent Hexane/i-PrOH = 90:10; temperature 40 °C; flow rate 1 mL/min). [α]D = −63.0 (c = 0.5, EtOAc, 25 °C). lit.[24] [α]D = −69.1 (c = 0.83, MeOH, 26 °C).
rac-CMPO. White solid. Mp = 103–104 °C (lit.[30] 99–101 °C). HPLC analysis: (+)-(7R,7aS)-CMPO (RT 8.8 min) and (−)-(7S,7aR)-CMPO (RT 9.8 min); column CHIRALPAK IA-3 (15 cm); solvent Hexane/i-PrOH = 90:10; temperature 40 °C; flow rate 1 mL/min.

5. Conclusions

In conclusion, we were able to solve the problem of site-selective C–H oxygenation of the cyclic nitronate intermediate in the asymmetric synthesis of a potent PDE4 inhibitor CMPO by using tandem acylation/(3,3)-sigmatropic rearrangement. In comparison with the previous synthesis, this method afforded the required 3-oxymethyl-substituted 1,2-oxazine intermediate in a much higher yield (76% vs. 27%). This key intermediate could be readily converted into the target (−)-CMPO by the reductive contraction of the 1,2-oxazine ring followed by deprotection and carbamylation with Im2CO. A rapid epimerization of the C-6 acetal moiety was observed upon the reduction of the 5,6-dihydro-4H-1,2-oxazine ring with NaBH3CN in acetic acid. DFT calculations suggest that the epimerization is favored by an unprecedented double anchimeric assistance from a remote acyloxy group and the nitrogen atom of the 1,2-oxazine ring.

Supplementary Materials

The following are available online: NMR spectra for compounds 10, 17, 18, 18′, 19, 20 and CMPO, chiral phase HPLC chromatograms for rac-CMPO and (−)-CMPO, Cartesian coordinates, absolute energies for all optimized geometries.

Author Contributions

E.V.P. carried out synthesis, separation, and purification of compounds; I.S.G. performed DFT calculations; S.L.I. collaborated in the discussion and interpretation of the results, manuscript editing; A.Y.S. supervised the whole research, including conceptualization, methodology, data curation and original draft preparation. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Russian Science Foundation (grant 17-13-01411).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Denmark, S.E.; Thorarensen, A. Tandem [4 + 2]/[3 + 2] Cycloadditions of Nitroalkenes. Chem. Rev. 1996, 96, 137–166. [Google Scholar] [CrossRef] [PubMed]
  2. Tabolin, A.A.; Sukhorukov, A.Y.; Ioffe, S.L.; Dilman, A.D. Recent Advances in the Synthesis and Chemistry of Nitronates. Synthesis 2017, 49, 3255–3268. [Google Scholar] [CrossRef]
  3. Mukaijo, Y.; Yokoyama, S.; Nishiwaki, N. Comparison of Substituting Ability of Nitronate versus Enolate for Direct Substitution of a Nitro Group. Molecules 2020, 25, 2048. [Google Scholar] [CrossRef] [PubMed]
  4. de Carvalho, L.L.; Burrow, R.A.; Pereira, V.L.P. Diastereoselective synthesis of nitroso acetals from (S,E)-γ-aminated nitroalkenes via multicomponent [4 + 2]/[3 + 2] cycloadditions promoted by LiCl or LiClO4. Beilstein J. Org. Chem. 2013, 9, 838–845. [Google Scholar] [CrossRef] [PubMed]
  5. Kano, T.; Yamamoto, A.; Song, S.; Maruoka, K. Catalytic asymmetric syntheses of isoxazoline-N-oxides under phase-transfer conditions. Chem. Commun. 2011, 47, 4358–4360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Koc, E.; Kwon, O. Total syntheses of heliotridane and pseudoheliotridane through nitrodiene–acrylate 6π-electrocyclization/[3+2] cycloaddition. Tetrahedron 2017, 73, 4195–4200. [Google Scholar] [CrossRef]
  7. Creech, G.S.; Kwon, O. Tandem 6π-Electrocyclization and Cycloaddition of Nitrodienes to Yield Multicyclic Nitroso Acetals. J. Am. Chem. Soc. 2010, 132, 8876–8877. [Google Scholar] [CrossRef] [Green Version]
  8. Zhu, C.-Y.; Deng, X.-M.; Sun, X.-L.; Zheng, J.-C.; Tang, Y. Highly enantioselective synthesis of isoxazoline N-oxides. Chem. Commun. 2008, 6, 738–740. [Google Scholar] [CrossRef]
  9. Streitferdt, V.; Haindl, M.H.; Hioe, J.; Morana, F.; Renzi, P.; von Rekowski, F.; Zimmermann, A.; Nardi, M.; Zeitler, K.; Gschwind, R.M. Unprecedented Mechanism of an Organocatalytic Route to Conjugated Enynes with a Junction to Cyclic Nitronates. Eur. J. Org. Chem. 2019, 2019, 328–337. [Google Scholar] [CrossRef] [Green Version]
  10. Jiang, H.; Elsner, P.; Jensen, K.L.; Falcicchio, A.; Marcos, V.; Jørgensen, K.A. Achieving Molecular Complexity by Organocatalytic One-Pot Strategies—A Fast Entry for Synthesis of Sphingoids, Amino Sugars, and Polyhydroxylated α-Amino Acids. Angew. Chem. Int. Ed. 2009, 48, 6844–6848. [Google Scholar] [CrossRef]
  11. Baiazitov, R.Y.; Denmark, S.E. Tandem [4 + 2]/[3 + 2] Cycloadditions. In Methods and Applications of Cycloaddition Reactions in Organic Syntheses; Nishiwaki, N., Ed.; John Wiley & Sons: Hoboken, NJ, USA, 2014; pp. 471–550. [Google Scholar]
  12. Denmark, S.E.; Martinborough, E.A. Enantioselective Total Syntheses of (+)-Castanospermine, (+)-6-Epicastanospermine, (+)-Australine, and (+)-3-Epiaustraline. J. Am. Chem. Soc. 1999, 121, 3046–3056. [Google Scholar] [CrossRef]
  13. Denmark, S.E.; Thorarensen, A.; Middleton, D.S. Tandem [4 + 2]/[3 + 2] Cycloadditions of Nitroalkenes. 9. Synthesis of (−)-Rosmarinecine. J. Am. Chem. Soc. 1996, 118, 8266–8277. [Google Scholar] [CrossRef]
  14. Denmark, S.E.; Baiazitov, R.Y.; Nguyen, S.T. Tandem double intramolecular [4 + 2]/[3 + 2] cycloadditions of nitroalkenes: Construction of the pentacyclic core structure of daphnilactone B. Tetrahedron 2009, 65, 6535–6548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Denmark, S.E.; Montgomery, J.I.; Kramps, L.A. Synthesis, X-ray Crystallography, and Computational Analysis of 1-Azafenestranes. J. Am. Chem. Soc. 2006, 128, 11620–11630. [Google Scholar] [CrossRef]
  16. Denmark, S.E.; Montgomery, J.I. Synthesis of cis,cis,cis,cis-[5.5.5.4]-1-Azafenestrane with Discovery of an Unexpected Dyotropic Rearrangement. Angew. Chem. Int. Ed. 2005, 44, 3732–3736. [Google Scholar] [CrossRef]
  17. For a review see: Sukhorukov, A.Y. C-H Reactivity of the α-Position in Nitrones and Nitronates. Adv. Synth. Catal. 2020, 362, 724–754. [Google Scholar] [CrossRef]
  18. Tishkov, A.A.; Lesiv, A.V.; Khomutova, Y.A.; Strelenko, Y.A.; Nesterov, I.D.; Antipin, M.Y.; Ioffe, S.L.; Denmark, S.E. 2-Silyloxy-1,2-oxazines, a New Type of Acetals of Conjugated Nitroso Alkenes. J. Org. Chem. 2003, 68, 9477–9480. [Google Scholar] [CrossRef]
  19. Sukhorukov, A.Y.; Kapatsyna, M.A.; Yi, T.L.T.; Park, H.R.; Naumovich, Y.A.; Zhmurov, P.A.; Khomutova, Y.A.; Ioffe, S.L.; Tartakovsky, V.A. A General Metal-Assisted Synthesis of α-Halo Oxime Ethers from Nitronates and Nitro Compounds. Eur. J. Org. Chem. 2014, 2014, 8148–8159. [Google Scholar] [CrossRef]
  20. Naumovich, Y.A.; Buckland, V.E.; Sen’ko, D.A.; Nelyubina, Y.V.; Khoroshutina, Y.A.; Sukhorukov, A.Y.; Ioffe, S.L. Metal-assisted addition of a nitrate anion to bis(oxy)enamines. A general approach to the synthesis of α-nitroxy-oxime derivatives from nitronates. Org. Biomol. Chem. 2016, 14, 3963–3974. [Google Scholar] [CrossRef] [Green Version]
  21. Tabolin, A.A.; Lesiv, A.V.; Khomutova, Y.A.; Nelyubina, Y.V.; Ioffe, S.L. Rearrangement of 3-alkylidene-2-siloxy-tetrahydro-1,2-oxazines (ASENA). A new approach toward the synthesis of 3-α-hydroxyalkyl-5,6-dihydro-4H-1,2-oxazines. Tetrahedron 2009, 65, 4578–4592. [Google Scholar] [CrossRef]
  22. Naumovich, Y.A.; Golovanov, I.S.; Sukhorukov, A.Y.; Ioffe, S.L. Addition of HO-Acids to N,N-Bis(oxy)enamines: Mechanism, Scope and Application to the Synthesis of Pharmaceuticals. Eur. J. Org. Chem. 2017, 2017, 6209–6227. [Google Scholar] [CrossRef]
  23. Zhmurov, P.A.; Khoroshutina, Y.A.; Novikov, R.A.; Golovanov, I.S.; Sukhorukov, A.Y.; Ioffe, S.L. Divergent Reactivity of In Situ Generated Metal Azides: Reaction with N,N-Bis(oxy)enamines as a Case Study. Chem. Eur. J. 2017, 23, 4570–4578. [Google Scholar] [CrossRef] [PubMed]
  24. Zhmurov, P.A.; Sukhorukov, A.Y.; Chupakhin, V.I.; Khomutova, Y.V.; Ioffe, S.L.; Tartakovsky, V.A. Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline’s highly potent Rolipram analogues. Org. Biomol. Chem. 2013, 11, 8082–8091. [Google Scholar] [CrossRef] [PubMed]
  25. Sukhorukov, A.Y.; Boyko, Y.D.; Ioffe, S.L.; Khomutova, Y.A.; Nelyubina, Y.V.; Tartakovsky, V.A. Synthesis of PDE IVb Inhibitors. 1. Asymmetric Synthesis and Stereochemical Assignment of (+)- and (−)-7-[3-(Cyclopentyloxy)-4-methoxyphenyl]hexahydro-3H-pyrrolizin-3-one. J. Org. Chem. 2011, 76, 7893–7900. [Google Scholar] [CrossRef] [PubMed]
  26. Kokuev, A.O.; Antonova, Y.A.; Dorokhov, V.S.; Golovanov, I.S.; Nelyubina, Y.V.; Tabolin, A.A.; Sukhorukov, A.Y.; Ioffe, S.L. Acylation of Nitronates: [3,3]-Sigmatropic Rearrangement of in Situ Generated N-Acyloxy,N-oxyenamines. J. Org. Chem. 2018, 83, 11057–11066. [Google Scholar] [CrossRef]
  27. Brackeen, M.F.; Stafford, J.A.; Cowan, D.J.; Brown, P.J.; Domanico, P.L.; Feldman, P.L.; Rose, D.; Strickland, A.B.; Veal, J.M.; Verghese, M. Design and Synthesis of Conformationally Constrained Analogs of 4-(3-Butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as Potent Inhibitors of cAMP-Specific Phosphodiesterase. J. Med. Chem. 1995, 38, 4848–4854. [Google Scholar] [CrossRef]
  28. Jackson, E.K.; Carcillo, J.A. Treatment of Sepsis-Induced Acute Renal Failure. U.S. Patent 5849774, 15 December 1998. [Google Scholar]
  29. Mulhall, A.M.; Droege, C.A.; Ernst, N.E.; Panos, R.J.; Zafar, M.A. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: A review of current and developing drugs. Exp. Opin. Investig. Drugs 2015, 24, 1597–1611. [Google Scholar] [CrossRef]
  30. Zhmurov, P.A.; Tabolin, A.A.; Sukhorukov, A.Y.; Lesiv, A.V.; Klenov, M.S.; Khomutova, Y.A.; Ioffe, S.L.; Tartakovsky, V.A. Synthesis of phosphodiesterase IVb inhibitors 2. Stereoselective synthesis of hexahydro-3H-pyrrolo[1,2-c]imidazol-3-one and tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one derivatives. Russ. Chem. Bull. 2011, 60, 2390–2395. [Google Scholar] [CrossRef]
  31. Yasuo, T.; Norihiko, Y.; Hiroko, M.; Toshihide, K.; Masahiro, A.; Yutaka, M. Synthesis and a Novel Fragmentation of 6-Alkoxy-5,6-dihydro-4H-1,2-oxazine 2-Oxide. Bull. Chem. Soc. Jpn. 1988, 61, 461–465. [Google Scholar]
  32. Sukhorukov, A.Y.; Ioffe, S.L. Chemistry of Six-Membered Cyclic Oxime Ethers. Application in the Synthesis of Bioactive Compounds. Chem. Rev. 2011, 111, 5004–5041. [Google Scholar] [CrossRef]
  33. Zimmer, R.; Arnold, T.; Homann, K.; Reissig, H.-U. An Efficient and Simple Synthesis of 3,4,5,6-Tetrahydro-2H-1,2-oxazines by Sodium Cyanoborohydride Reduction of 5,6-Dihydro-4H-1,2-oxazines. Synthesis 1994, 1994, 1050–1056. [Google Scholar] [CrossRef]
  34. Demchenko, A.V.; Rousson, E.; Boons, G.-J. Stereoselective 1,2-cis-galactosylation assisted by remote neighboring group participation and solvent effects. Tetrahedron Lett. 1999, 40, 6523–6526. [Google Scholar] [CrossRef]
  35. Ma, Y.; Lian, G.; Li, Y.; Yu, B. Identification of 3,6-di-O-acetyl-1,2,4-O-orthoacetyl-α-d-glucopyranose as a direct evidence for the 4-O-acyl group participation in glycosylation. Chem. Commun. 2011, 47, 7515–7517. [Google Scholar] [CrossRef] [PubMed]
  36. Beaver, M.G.; Billings, S.B.; Woerpel, K.A. C-Glycosylation Reactions of Sulfur-Substituted Glycosyl Donors:  Evidence against the Role of Neighboring-Group Participation. J. Am. Chem. Soc. 2008, 130, 2082–2086. [Google Scholar] [CrossRef] [PubMed]
  37. Stalford, S.A.; Kilner, C.A.; Leach, A.G.; Turnbull, W.B. Neighbouring group participation vs. addition to oxacarbenium ions: Studies on the synthesis of mycobacterial oligosaccharides. Org. Biomol. Chem. 2009, 7, 4842–4852. [Google Scholar] [CrossRef] [PubMed]
  38. Yang, B.; Yang, W.; Ramadan, S.; Huang, X. Pre-Activation-Based Stereoselective Glycosylations. Eur. J. Org. Chem. 2018, 2018, 1075–1096. [Google Scholar] [CrossRef]
  39. Crich, D.; Hu, T.; Cai, F. Does Neighboring Group Participation by Non-Vicinal Esters Play a Role in Glycosylation Reactions? Effective Probes for the Detection of Bridging Intermediates. J. Org. Chem. 2008, 73, 8942–8953. [Google Scholar] [CrossRef] [Green Version]
  40. Komarova, B.S.; Tsvetkov, Y.E.; Nifantiev, N.E. Design of α-Selective Glycopyranosyl Donors Relying on Remote Anchimeric Assistance. Chem. Rec. 2016, 16, 488–506. [Google Scholar] [CrossRef]
Sample Availability: Samples of racemic and enantiopure PDE4 inhibitor CMPO are available from the authors.
Molecules 25 03613 sch001 550
Scheme 1. Approaches towards modification of cyclic nitronates. (a) Synthesis of cyclic nitronates from nitroalkenes; (b) 1,3-Dipolar addition with cyclic nitronates and its application in total synthesis; (c) C-H functionalization of cyclic nitronates via N-siloxyenamines (route 1); (d) C-H functionalization of cyclic nitronates via [3,3]-rearrangement of N-acyloxyenamines (route 2).
Scheme 1. Approaches towards modification of cyclic nitronates. (a) Synthesis of cyclic nitronates from nitroalkenes; (b) 1,3-Dipolar addition with cyclic nitronates and its application in total synthesis; (c) C-H functionalization of cyclic nitronates via N-siloxyenamines (route 1); (d) C-H functionalization of cyclic nitronates via [3,3]-rearrangement of N-acyloxyenamines (route 2).
Molecules 25 03613 sch001
Molecules 25 03613 sch002 550
Scheme 2. Previous asymmetric synthesis of (−)-CMPO.
Scheme 2. Previous asymmetric synthesis of (−)-CMPO.
Molecules 25 03613 sch002
Molecules 25 03613 sch003 550
Scheme 3. Problems associated with C-6 epimerization in the LA-assisted functionalization of cyclic nitronate 10. (a) Functionalization of cyclic nitronate 10; (b) Mechanism of epimerization at C-6; (c) Hydride reduction of 4,6-cis-1,2-oxazines.
Scheme 3. Problems associated with C-6 epimerization in the LA-assisted functionalization of cyclic nitronate 10. (a) Functionalization of cyclic nitronate 10; (b) Mechanism of epimerization at C-6; (c) Hydride reduction of 4,6-cis-1,2-oxazines.
Molecules 25 03613 sch003
Molecules 25 03613 sch004 550
Scheme 4. Tandem acylation/(3,3)-rearrangement of nitronate 10.
Scheme 4. Tandem acylation/(3,3)-rearrangement of nitronate 10.
Molecules 25 03613 sch004
Molecules 25 03613 sch005 550
Scheme 5. Cyanoborohydride reduction of 3-hydroxymethyl 1,2-oxazine 13 and its pivalate 17.
Scheme 5. Cyanoborohydride reduction of 3-hydroxymethyl 1,2-oxazine 13 and its pivalate 17.
Molecules 25 03613 sch005
Molecules 25 03613 sch006 550
Scheme 6. Conversion of 1,2-oxazines 18 and 18′ into target PDE4 inhibitor (−)-CMPO.
Scheme 6. Conversion of 1,2-oxazines 18 and 18′ into target PDE4 inhibitor (−)-CMPO.
Molecules 25 03613 sch006
Molecules 25 03613 sch007 550
Scheme 7. Plausible mechanism of the epimerization at the C-6 position in 1,2-oxazine 18. Ar − 4-methoxy-3-cyclopentyloxyphenyl, G*—trans-2-phenylcyclohexyl. DFT calculations: MN15/Def2TZVP (AcOH, smd), LA was not included in the calculations.
Scheme 7. Plausible mechanism of the epimerization at the C-6 position in 1,2-oxazine 18. Ar − 4-methoxy-3-cyclopentyloxyphenyl, G*—trans-2-phenylcyclohexyl. DFT calculations: MN15/Def2TZVP (AcOH, smd), LA was not included in the calculations.
Molecules 25 03613 sch007
Molecules 25 03613 g001 550
Figure 1. Numeration of atoms in products 17–20.
Figure 1. Numeration of atoms in products 17–20.
Molecules 25 03613 g001

Share and Cite

MDPI and ACS Style

Pospelov, E.V.; Golovanov, I.S.; Ioffe, S.L.; Sukhorukov, A.Y. The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study. Molecules 2020, 25, 3613. https://doi.org/10.3390/molecules25163613

AMA Style

Pospelov EV, Golovanov IS, Ioffe SL, Sukhorukov AY. The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study. Molecules. 2020; 25(16):3613. https://doi.org/10.3390/molecules25163613

Chicago/Turabian Style

Pospelov, Evgeny V., Ivan S. Golovanov, Sema L. Ioffe, and Alexey Yu. Sukhorukov. 2020. "The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study" Molecules 25, no. 16: 3613. https://doi.org/10.3390/molecules25163613

APA Style

Pospelov, E. V., Golovanov, I. S., Ioffe, S. L., & Sukhorukov, A. Y. (2020). The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study. Molecules, 25(16), 3613. https://doi.org/10.3390/molecules25163613

Article Metrics

Back to TopTop